BCTXZ
BriaCell Therapeutics Corp. WarrantKey Statistics
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapy treatments for cancer, particularly breast cancer. Its proprietary candidate, Bria-IMT, has demonstrated promising efficacy in initial clinical trials, reflecting the company's commitment to addressing critical unmet needs in oncology. With a robust research and development foundation and a seasoned leadership team, BriaCell is strategically positioned to make significant strides in cancer therapeutics, striving to improve patient outcomes in an evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-31.92M |
| Operating Margin | 0.00% |
| Return on Equity | -175.30% |
| Return on Assets | -90.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.32 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $7.86M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCTXZ and any ticker you trade — then tracks every position and per-strategy win rate.